Tissue Engineering for Drug Development and Substance Testing
TEDD Partners have access to view and download publications and presentations. To access please follow the link. Password is provided with the separate email during registration process. If you forgot your password please contact us.
Some of the material is available for selected audience (with password).
TEDD & 3R Workshop organized in collaboration with Animalfree Research
Place: Wädenswil, Switzerland
Workshop is recognized by the Federation of Swiss Cantonal Veterinary Officers (VSKT) as a half-day day further education for researchers. Certificate
The 3Rs – a Vision and a Challenge.
The recognition of a wide range of animals as sentient beings has placed a moral dilemma squarely in the path of scientific research using them. It has become clear that animal experimentation should be done with greatest care, consideration, and ideally, not at all. This is easier said than done but for reasons of ethics, regulation, reproducibility and costs there are worldwide efforts underway to Refine, Reduce, and to Replace (3R) animal experiments.
One such strategy is to use sophisticated in vitro cell and tissue models using human cells. As good as this might sound, there is still a widespread use of an animal product in cell cultivation, namely fetal calf serum (FCS). For many decades it has become an invaluable and essential admixture to animal and human cell culture media. FCS contains crucial growth factors both known and unknown, that keep cell growing in culture. FCS is a byproduct of the meat and dairy industry all over the world. Its quality and therefore its effects on cell cultures are highly variable and cell type-dependent. Not only has this driven innumerable PhD students into despair, the current reproduction crisis of experimental data might even be based on variable FCS quality. Clearly, as long as fetal calf serum is used in our cell culture facilities, the 3Rs are not fully realized. In addition, the preparation of human cells for cell therapy without animal components is an impending future requirement by regulatory bodies. So why not simply replace serum and continue the good work with a good conscience?
The answer is that it is not that simple at all. Without serum cells do not thrive, so replacement factors must be found that keep the cells going. Again, this is cell type-dependent (there are over 200 different cells in the human body). Each single component of culture medium must be sourced from animal-free origin and this requires a gap-less documentation chain. However, at the end of the day, a fully animal-free culture medium must give the scientist the same potency and cell behavior, and this is currently one of the most important bottlenecks preventing a more widespread use of animal-free culture media.
We dedicate this 3R meeting to highlight these challenges of serum-free cell culture. Representatives from the cell culture industry, and applied scientists will throw light on current issues with both serum and its replacement.
Activities on Microphysiological Systems and 3D Tissue Engineering in the Basel Area
Place: Basel, Switzerland
The BioEngineering Laboratory (BEL) within the Department of Biosystem Science and Engineering (D-BSSE) host the next TEDD visit to highlight the combined effort of the Basel area in the field of microphysiological systems and 3D tissue engineering by presenting research from FMI, University of Basel, FHNW and D-BSSE.
It is our pleasure to invite you to visit ETH Zürich in Basel for an afternoon of talks to learn about microphysiological system and 3D tissue engineering - related research and innovation. You will also have the chance to visit laboratories of the Department of Biosystems Science and Engineering.
- Dr. Kasper Renggli
- Dr. Olivier Frey
- Prof. Andreas Hierlemann
TEDD Annual Meeting 2016
ETH Biotechnology Day
Place: ETH Hönggerberg, Zürich Switzerland
Visit to ETH-Hönggerberg for an afternoon of lab tours to learn about biotechnology – related research and innovation. We saw laboratories of the Institute for Biomechanics with electrospinning, bioprinting, 3D imaging, mechanical simulation and bone testing. We visited the Innovation & Entrepreneur Lab which is an incubator for ETH Biotech spinoffs. Finally, we saw the Stem Cell Biology and Disease Modeling group and learnt about their organoid research.
Guided Laboratory Visits
(1) Laboratory for Bone Biomechanics, Dr. Marina Rubert, Dr. Jolanda Baumgartner
(2) Laboratory for Orthopadic Technologies, Remo Affentranger
(3) Tissue Mechanobiology Group, Oddny Björgvinsdottir, Dmitriy Alexeev
(4) Cartilage Engineering + Regeneration, Matti Kesti
(5) ETH Innovation and Entrepreneur Lab (Hosted by CellSpring AG), Dr. Christropher Millan
(6) Stem Cell Biology and Disease Modeling, Prof. Gerald Schwank
- Prof. Stephen Ferguson, Dr. Karin Würtz, Laboratory for Orthopaedic Technology
- Prof. Marcy Zenobi-Wong, Cartilage Engineering and Regeneration
- Dr. Marina Rubert, Laboratory for Bone Biomechanics
Cell Therapy and Tissue Engineering in Ticino
Place: Lugano, Switzerland
In the last decade, the growth of the biotech sector in the Italian-speaking Switzerland has become increasingly important for the economy of the region and for the surrounding scientific environment, soon to be empowered by a new Faculty of Biomedical Sciences at the local Università della Svizzera Italiana (USI). Moreover, Regenerative Medicine research is being carried out at SIRM, a new research facility located in Taverne and shared by different companies and research institutions. In order to discover and have a deeper look on the evolving scientific and industrial framework of Ticino Canton, the next TEDD event will be held in Lugano, hosted by Cardiocentro Ticino and the Swiss Institute for Regenerative Medicine. During the event, speakers from the academic, clinical and industrial sector of the region will present their activities and will discuss the ways in which they can connect and collaborate with other partners. Likewise, participants will have the opportunity to visit SIRM Laboratories, have a direct contact with research groups sharing information about methods and reasearch activities.
This is the first TEDD event organized in region of Ticino. We encourage you take the unique opportunity to meet the most important academic and industrial players of this area.
Visit to Roche Diagnostics
Olten Meeting 2015
biotechnet Switzerland - Annual Meeting in Olten 2015
The traditional Olten Meeting presents this year two topics:
- 3D bioprinting
TEDD Annual Meeting 2015
CTI Medtech Award 2015
The CTI Medtech initiative has been part of the services of the Innovation Promotion Agency CTI since 1997, with more than 465 collaborative projects and 50 startups being supported by CTI in that time. This year’s Medtech Event will showcase successful projects, provide insights into current trends and share views and opinions about future developments in the field of medical technology. In addition, CTI Start-up Promotion invites young entrepreneurs of the Medtech Industry to an informal roundtable with senior entrepreneurs who will share their experience and answer questions about raising and leading a company successfully (participation by invitation only).
Symposium Frontiers in Personalized Medicine 2015
- Current and future trends in personalized medicine, Dr. Bruce Jordan, Roche Diagnostics
- International Ltd Challenges of personalized health for clinical medicine, Prof. Dr. Peter Meier-Abt, Swiss Academy of Medical Sciences, Basel
- Implementing research in personalized medicine, Prof. Dr. Niko Beerenwinkel, ETH Zurich, Competence Center Personalized Medicine
- Osteosarcoma: Current perspectives and future developement, Prof. Dr. Bruno Fuchs, Sarcoma Center UZH, University Hospital Balgrist
- Gene therapy in ophthalmology – the TargetAMD project, Dr. Martina Kropp, University Hospital Geneva
- TEDD information, Prof. Dr. Ursula Graf-Hausner, Zurich University of Applied
- Sciences Exhibition slam
Advanced Drug Delivery Reviews (ADDR) theme edition
- Title page
- Thomas Hartung, 3D — A new dimension of in vitro research
- David W. Grainger, Cell-based drug testing; this world is not flat
- Anna Astashkina, David W. Grainger, Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments
- Adrian Ranga, Nikolche Gjorevski, Matthias P. Lutolf, Drug discovery through stem cell-based organoid models
- Claudio R. Thoma, Miriam Zimmermann, Irina Agarkova, Jens M. Kelm, Wilhelm Krek, 3D cell culture systems modeling tumor growth determinants in cancer target discovery
- Britta Weigelt, Cyrus M. Ghajar, Mina J. Bissell, The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer
- Maria Håkanson, Edna Cukierman, Mirren Charnley, Miniaturized pre-clinical cancer models as research and diagnostic tools
- Teresa M. DesRochers, Erica Palma, David L. Kaplan, Tissue-engineered kidney disease models
- Stephanie H. Mathes, Heinz Ruffner, Ursula Graf-Hausner, The use of skin models in drug development
- Christoph Giese, Uwe Marx, Human immunity in vitro — Solving immunogenicity and more
- Mark A. LaBarge, Bahram Parvin, James B. Lorens, Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics
- Mohammad R. Ebrahimkhani, Jaclyn A. Shepard Neiman, Micha Sam B. Raredon, David J. Hughes, Linda G. Griffith, Bioreactor technologies to support liver function in vitro
- Mandy B. Esch, Alec S.T. Smith, Jean-Matthieu Prot, Carlota Oleaga, James J. Hickman, Michael L. Shuler, How multi-organ microdevices can help foster drug development
- Jered V. McGivern, Allison D. Ebert, Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments
- Adrian Roth, Thomas Singer, The application of 3D cell models to support drug safety assessment: Opportunities & challenges
- Ellen L. Berg, Yu-Chih Hsu, Jonathan A. Lee, Consideration of the cellular microenvironment: Physiologically relevant co-culture systems in drug discovery
- Bo Ri Seo, Peter DelNero, Claudia Fischbach, In vitro models of tumor vessels and matrix: Engineering approaches to investigate transport limitations and drug delivery in cancer
- Saurabh Vyawahare, Qiucen Zhang, Alexandra Lau, Robert H. Austin, In vitro microbial culture models and their application in drug development
- Stefan M. Schmitt, Mazhar Gull, André W. Brändli, Engineering Xenopus embryos for phenotypic drug discovery screening
- Linda P. O'Reilly, Cliff J. Luke, David H. Perlmutter, Gary A. Silverman, Stephen C. Pak, C. elegans in high-throughput drug discovery
- Maximilian Y. Emmert, Robert W. Hitchcock, Simon P. Hoerstrup, Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration